0.21
-0.007(-3.21%)
Currency In USD
| Previous Close | 0.22 |
| Open | 0.21 |
| Day High | 0.22 |
| Day Low | 0.21 |
| 52-Week High | 1.75 |
| 52-Week Low | 0.17 |
| Volume | 1.52M |
| Average Volume | 19.05M |
| Market Cap | 7.12M |
| PE | 0.1 |
| EPS | 2.06 |
| Moving Average 50 Days | 0.24 |
| Moving Average 200 Days | 0.51 |
| Change | -0.01 |
If you invested $1000 in Theriva Biologics, Inc. (TOVX) 10 years ago, it would be worth $0.01 as of January 14, 2026 at a share price of $0.211. Whereas If you bought $1000 worth of Theriva Biologics, Inc. (TOVX) shares 5 years ago, it would be worth $1.11 as of January 14, 2026 at a share price of $0.211.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
GlobeNewswire Inc.
Dec 29, 2025 1:00 PM GMT
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive desi
Theriva Biologics Provides Response to Unusual Market Action
GlobeNewswire Inc.
Oct 24, 2025 6:31 PM GMT
ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high un
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 16, 2025 12:11 PM GMT
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high un